Solasia Pharma K.K.

Solasia Pharma K.K. is a Japan-based group principally engaged in the development and sale of pharmaceuticals. Expanding and developing its drug pipeline, primarily in oncology, is a key business activity. According to the notes to the interim consolidated financial statements, as of 30 June 2026, several product and development-related transactions and activities were underway, including an exclusive distribution-rights licence for Brazil centered on Episil, a licence agreement to expand Sancuso into China, and progress in the clinical development of products such as SP-05 and SP-04. For the fiscal year ending June 2026, the condensed interim consolidated financial statements reported revenue of ¥8 million, primarily from Episil product sales, gross profit of ¥6 million, an operating loss of ¥5,710 million, an interim loss of ¥5,709 million, and interim comprehensive loss attributable to owners of the parent of approximately ¥5,709 million. Cash and cash equivalents at the end of the interim period were ¥1,289 million, total assets were approximately ¥18,970 million, and equity attributable to owners of the parent was approximately ¥1,450 million. Due to the introduction of a stock-based compensation trust (J-ESOP), treasury shares are deducted in calculating the weighted-average number of shares outstanding, and diluted per-share figures are therefore generally the same as basic figures.